A

Amneal Intermediate Inc
NASDAQ:AMRX

Watchlist Manager
Amneal Intermediate Inc
NASDAQ:AMRX
Watchlist
Price: 8.46 USD -2.76% Market Closed
Market Cap: 2.6B USD
Have any thoughts about
Amneal Intermediate Inc?
Write Note

Amneal Intermediate Inc
Revenue

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Amneal Intermediate Inc
Revenue Peer Comparison

Comparables:
JNJ
BMY
PFE
MRK
LLY

Competitive Revenue Analysis
Latest Figures & CAGR of Competitors

Company Revenue CAGR 3Y CAGR 5Y CAGR 10Y
A
Amneal Intermediate Inc
NASDAQ:AMRX
Revenue
$2.4B
CAGR 3-Years
6%
CAGR 5-Years
8%
CAGR 10-Years
17%
Johnson & Johnson
NYSE:JNJ
Revenue
$87.7B
CAGR 3-Years
-1%
CAGR 5-Years
1%
CAGR 10-Years
2%
Bristol-Myers Squibb Co
NYSE:BMY
Revenue
$46.5B
CAGR 3-Years
2%
CAGR 5-Years
14%
CAGR 10-Years
11%
Pfizer Inc
NYSE:PFE
Revenue
$55.6B
CAGR 3-Years
0%
CAGR 5-Years
10%
CAGR 10-Years
1%
Merck & Co Inc
NYSE:MRK
Revenue
$62.5B
CAGR 3-Years
12%
CAGR 5-Years
7%
CAGR 10-Years
4%
Eli Lilly and Co
NYSE:LLY
Revenue
$38.9B
CAGR 3-Years
13%
CAGR 5-Years
12%
CAGR 10-Years
6%

Amneal Intermediate Inc
Revenue Breakdown

Breakdown by Geography
Amneal Intermediate Inc

Not Available

Breakdown by Segments
Amneal Intermediate Inc

Total Revenue: 2.4B USD
100%
Generics: 1.5B USD
61.5%
Avkare: 531.7m USD
22.2%
Specialty: 390.5m USD
16.3%

See Also

What is Amneal Intermediate Inc's Revenue?
Revenue
2.4B USD

Based on the financial report for Dec 31, 2023, Amneal Intermediate Inc's Revenue amounts to 2.4B USD.

What is Amneal Intermediate Inc's Revenue growth rate?
Revenue CAGR 10Y
17%

Over the last year, the Revenue growth was 8%. The average annual Revenue growth rates for Amneal Intermediate Inc have been 6% over the past three years , 8% over the past five years , and 17% over the past ten years .

Back to Top